IN THIS SECTION
Overview
Publications
News

Contact Us
Ordering



News Articles
Success Supports Bioscience Study
BY MARK WATSON
DECEMBER 15, 2003


Two years into Genome Explorations' young life, the company's success backs up a study commissioned by the Mid-South's leading chief executives, that the Memphis area has clear advantages as a bioscience research and industry center.

Genome Explorations processes and analyzes DNA samples using the Affymetrix GeneChip and Genome Explorations' own information technology systems. Also known as a microarray, a gene chip contains thousands of human genes against which DNA samples are compared to determine the presence or absence of proteins generated by cancer cells.

"The importance of this microarray technology is that it's how you begin to focus on specific genes," said Mitchell Horowitz, who authored a Battelle Memorial Institute study of Memphis's potential as a center of bioscience research and industry.

Focusing on specific genes helps drug discovery, which is one of Memphis's strengths cited in the Battelle study, commissioned by Memphis Tomorrow. Chief executives of several of Memphis's largest companies formed Memphis Tomorrow to advance local citizens' well-being via "significant, breakthrough initiatives."

The genetic "global snapshot" and interpretation provided by Genome Explorations helps researchers identify promising leads for disease treatment earlier, said Dr. Divyen Patel, who founded the company in 2001. It also helps provide more accurate prognosis for how specific patients likely will respond to treatment.

Genome Explorations made a profit in its first quarter and plans to open offices in Europe in the first half of 2004. The company provides microarray analysis and gene expression profiling for more than 70 organizations worldwide. Among them are pharmaceutical companies, research institutions and biotech start-ups.

"We're pretty much the market leaders for this type of technology," Patel said.

The FedEx hub provides one advantage for Genome Explorations, Patel said. "We have really reliable sample delivery," he said.
Patel worked and developed systems used at Genome Explorations with Dr. Clayton Naeve, St. Jude Children's Research Hospital chief of molecular biotechnology and director of the Hartwell Center for Bioinformatics and Biotechnology, who now sits on Genome Explorations' board.

"Our main goal is to attract more and more researchers," Patel said.
The company hoped to get local client institutions as clients in its first year, expand nationally in its second year, move into Europe in its third year and "go global" in the fourth year, Patel said. But by the end of Genome Explorations' first full year, it had already expanded worldwide with about 75 institutions, he said.

Patel recently returned from a trip to the United Kingdom, where he is negotiating an alliance with a Scottish company. Other alliances include Apocom Genomics, of Knoxville, VizX Labs, of Seattle, and the Southern Research Institute, of Birmingham.

Rhonda Jung, Southern Research Institute spokeswoman, said, "It's an area where we're focusing a lot of new attention and hoping to collaborate with companies like Genome Explorations."

SRI chose Genome Explorations because a number of SRI's researchers had experience with Patel and his colleagues, "so there was some comfort level there," said David Harris, SRI director of business development for drug discovery.

Patel said, "The good thing about all of our alliances so far is that they have approached us, instead of the other way around."
Patel and his colleagues hope to form companies to exploit microarray analysis research for specific diseases. The first such firm, developed under the Logical Genomics umbrella company, is Astrogene, which focuses on brain tumors.

These other companies would use Genome Explorations' gene expression profiling services.

SRI's Harris said, "There are some other joint projects where we believe their technology and connections into a specific niche in the marketplace, plus our full array of drug discovery and development services is a unique combination."



Copyright 2003, commercialappeal.com - Memphis, TN. All Rights Reserved.





Need to place an order? Simply download the appropriate order form and client agreement.